ENB Therapeutics Announces Clinical Trial Collaboration with Merck

  • ENB Therapeutics, Inc., a clinical-stage, biopharmaceutical company developing innovative, endothelin-based oncologics, today announced that it has entered into a clinical collaboration agreement with Merck (known as MSD outside the U.S. and Canada) to evaluate the combination of ENB-003, a first-in class endothelin B receptor (“ETBR”) inhibitor and Merck’s anti-PD-1 therapy, KEYTRUDA┬« (pembrolizumab), in a Phase 1/2 trial in patients with advanced solid tumors.

    Click Here to to Read More